Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Erythropoiesis-stimulating agents: friends or foes?

Shander A, Ozawa S, Gross I, Henry D.

Transfusion. 2013 Sep;53(9):1867-72. doi: 10.1111/trf.12328. No abstract available.

PMID:
24015936
2.

Current status of pharmacologic therapies in patient blood management.

Goodnough LT, Shander A.

Anesth Analg. 2013 Jan;116(1):15-34. doi: 10.1213/ANE.0b013e318273f4ae. Epub 2012 Dec 7. Review.

PMID:
23223098
4.

Erythropoietin in cancer-related anemia.

Fenner MH, Ganser A.

Curr Opin Oncol. 2008 Nov;20(6):685-9. doi: 10.1097/CCO.0b013e3283136971. Review.

PMID:
18841051
5.

Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.

Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI.

J Natl Cancer Inst. 2009 Dec 2;101(23):1633-41. doi: 10.1093/jnci/djp387. Epub 2009 Nov 10. Erratum in: J Natl Cancer Inst. 2010 Feb 24;102(4):282-3.

6.
7.

Erythropoietin as a pharmacologic alternative to blood transfusion in the surgical patient.

Goodnough LT.

Transfus Med Rev. 1990 Oct;4(4):288-96. Review. No abstract available.

PMID:
2134634
8.

Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.

Foley RN, Curtis BM, Parfrey PS.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1669-75. doi: 10.2215/CJN.02100508. Epub 2008 Oct 15.

9.

The role of recombinant growth factors in transfusion medicine.

Goodnough LT.

Br J Anaesth. 1993 Jan;70(1):80-6. Review. No abstract available.

PMID:
8431340
10.

[Current issues in erythropoietin therapy of renal anemia].

Zakar G.

Lege Artis Med. 2007 Oct;17(10):667-73. Review. Hungarian.

PMID:
19227596
11.

Cytokine biology. Implications for transfusion medicine.

Adamson JW.

Cancer. 1991 May 15;67(10 Suppl):2708-11. Review.

12.

Changing transfusion practices in orthopedic surgery.

Spence RK, Sculco TP, Keating EM, Nelson CL.

Orthopedics. 1995 Sep;18(9):842-5. No abstract available.

PMID:
8570487
13.

Symposium: options in transfusion therapy.

Nelson CL, Keating EM, Murray DG, Schurman DJ.

Contemp Orthop. 1994 Oct;29(4):283-94, 298-305. No abstract available.

PMID:
10150251
14.

[The effect of erythropoietin and Salmonella typhosa endotoxin on the survival of irradiated mice].

Tóth L, Fehér I.

Strahlentherapie. 1968 Sep;136(3):360-4. German. No abstract available.

PMID:
5685755
15.

Blood conservation in cardiac surgery: the Virginia Commonwealth University (VCU) experience.

Green JA.

J Cardiothorac Vasc Anesth. 2004 Aug;18(4 Suppl):18S-23S. No abstract available.

PMID:
15368201
16.

The effect of recombinant human erythropoietin therapy on red cell expansion during autologous blood donation.

Goodnough LT, Marcus RE.

Contemp Orthop. 1994 Dec;29(6):430-4. Review.

PMID:
10150254
17.

Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group.

Bessho M, Hirashima K, Asano S, Ikeda Y, Ogawa N, Tomonaga M, Toyama K, Nakahata T, Nomura T, Mizoguchi H, Yoshida Y, Niitsu Y, Kohgo Y.

Eur J Haematol. 1997 Apr;58(4):265-72.

PMID:
9186538
18.

Novel erythropoiesis-stimulating agents: a new era in anemia management.

Macdougall IC.

Clin J Am Soc Nephrol. 2008 Jan;3(1):200-7. Epub 2007 Dec 12. Review.

19.

Erythropoietin therapy versus red cell transfusion.

Goodnough LT.

Curr Opin Hematol. 2001 Nov;8(6):405-10. Review.

PMID:
11604583
20.

Management of chemotherapy-induced anemia.

Eguchi K.

Curr Opin Oncol. 1995 Jul;7(4):316-9. Review.

PMID:
7578378

Supplemental Content

Support Center